Clinical trials show that the effectiveness of NeuroStar Advanced Therapy is related to the patients’ previous antidepressants. All of the patients who were studied for Major Depressive Disorder had not received satisfactory improvement with previous treatments.

An effective and durable option for treating major depression.

The National Institute of Mental Health funded a randomized, controlled trial that treated 307 patients with the NeuroStar Advanced Therapy TMS for 4 to 6 weeks.

Patients were divided into two groups:

Patients who have failed to improve their depression symptoms after a single antidepressant treatment of adequate dose and duration are called low treatment resistance.

Patients who have failed to improve their depression symptoms after a multiple (2-14) antidepressant treatments of adequate dose and duration are called high treatment resistance.

Patients who received the advanced therapy were four times more likely to achieve a cure than patients who did not. 1 in 2 patients experienced a significant improvement in their depression symptoms. Patients who received NeuroStar Advanced Therapy experienced a significant improvement in their physical symptoms associated with depression.

Durability of TMS Treatments

The effects of the system have been established over a year.

In a trial with physician directed standard of care, patients who received treatment and reported their symptoms at 3, 6, 9 and 12 months were able to use the therapy with antidepressants as needed. By the end transcranial magnetic stimulation of the year, 2 out of 3 patients who had responded or completely responded after treatment remained at their symptom levels.

Only 1 in 3 patients need to come back for maintenance sessions after the treatment period is over.

Treatment Algorithm

A new tool has been developed by Neuronetics to help educate patients on the best practices of treating depression. If your first line antidepressants stop working, you should consider using the Best Practices Treatment Guideline for Depression. The guideline is based on the 2010 American Psychiatric Association’s practice guidelines and the indication for use of NeuroStar TMS Therapy.

Adult patients with major depression who have failed to achieve satisfactory improvement from prior antidepressants are recommended for the treatment of NeuroStar Advanced Therapy.

The Treatment Algorithm is an effective illustration of the use of NeuroStar Advanced Therapy TMS early on in the treatment of depression.

Patients who have not received prior treatment for depression have not been studied.

View TMS Therapy safety data

You may also like...

Leave a Reply

Your email address will not be published.